Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Caris Life Sciences to Showcase Extensive Research with Leading Cancer Centers Reflecting Its Commitment to Improving Outcomes for Patients at ASCO 2022

Research results from 45 studies across more than 20 various solid tumor types demonstrate the impact of Caris’ approach to molecular profiling across the continuum of cancer care

Caris Life Sciences (Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare , announced that the company and partners within its Precision Oncology Alliance (POA) will collectively present 45 studies across more than 20 various solid tumor types at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7, 2022 (Booth #22081).

Latest Aithority Insights: Qisda Selects MOV.AI Robotics Engine Platform to Power its Autonomous Mobile Robots

“The breadth of research being presented at ASCO illustrates the power of comprehensive molecular profiling and large-scale collaboration between more than 60 sites to address some of the biggest challenges in cancer care and precision oncology today,” said Chadi Nabhan, M.D., MBA, FACP, Chairman of the Caris Precision Oncology Alliance. “The findings of these studies could help improve outcomes for patients with difficult-to-treat cancers and pioneer new approaches to care across diverse tumor types and patient populations.”

Related Posts
1 of 27,458

“At Caris, our goal is to enable clinicians to make the best treatment choices, researchers to discover new targets, and the biopharmaceutical industry to develop the next breakthrough medicines,” said David Spetzler, M.S., Ph.D., MBA, President and Chief Scientific Officer of Caris. “These presentations show how our scientists and partners in the POA are using Caris’ unique AI-driven platform – which combines data from DNA (Whole Exome), RNA (Whole Transcriptome), and protein profiling with real-world clinical evidence from over 378,000 lifetime cases – to unravel the complexities of cancer. Ultimately, these discoveries could advance personalized cancer care and improve outcomes for many patients.”

Browse The Complete News About Aithority : Veniam and Single Digits Connect Mobile IoT Devices to Millions of Wi-Fi Hotspots

The Caris Precision Oncology Alliance includes 65 cancer centers and academic institutions in the United States and beyond. These institutions have early access to the extensive database and artificial intelligence platform within Caris to establish evidence-based standards for cancer profiling and molecular testing in oncology. By leveraging the comprehensive genomic, transcriptomic and proteomic data available through Caris molecular profiling, Caris seeks to provide this network with the ability to prioritize therapeutic options and determine which clinical trial opportunities may benefit their patients. POA members are also able to integrate with a growing portfolio of biomarker directed trials sponsored by biopharma. Additionally, as a member of the POA, institutions have access to Caris CODEai™, the most comprehensive data solution in the industry with cancer treatment information and real-world clinical outcomes evidence for over 275,000 patients covering over 1 million data points per patient.

Read More About Aithority News : Prism Software Releases Latest WorkPath Connect; A Low Cost, No-Code Data Integration Application

[To share your insights with us, please write to]

Comments are closed.